Drilldown: Medicines
Appearance
Medicines > onset
:
30–60 min
or
IOP lowering at 2 hours; max at 4 hours
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
:
30–60 min
or
IOP lowering at 2 hours; max at 4 hours
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
Use the filters below to narrow your results.
CNS stimulant (1) ·
NDRI (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Carbonic_anhydrase_inhibitors|Carbonic anhydrase inhibitor (topical)]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Glaucoma_medications|Glaucoma medication]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (1)
None (2) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
None (1) ·
2% ophthalmic solution (Trusopt); 2%/0.5% fixed combination with timolol (Cosopt, Cosopt PF) (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) ·
5 mg tablets; combination with metformin (1)
2.2 h (IR parent); ~3 h (XR parent) (1) ·
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~4 h (1) ·
~4 months in erythrocytes (carbonic anhydrase binding in red cells; not relevant to topical IOP duration)'"`UNIQ--ref-00000B0A-QINU`"' (1)
Category B (1) ·
Category C (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.

